Skyhawk Therapeutics gibt die endgültigen Ergebnisse nach 15 Monaten aus der klinischen Phase-1/2-Studie mit SKY-0515 bei Patienten mit Huntington-Krankheit bekannt

Skyhawk Therapeutics reported final 15-month Phase 1/2 results for oral Huntington's candidate SKY-0515, with a +1.59-point cUHDRS advantage versus an overlap-weighted external natural-history control (p<0.001). Treated patients improved by 0.94 points from baseline while controls declined by 0.65 points; all four functional, motor and cognitive cUHDRS components were statistically significant. At 9 mg, SKY-0515 reduced mutant huntingtin protein by more than 60% and PMS1 mRNA by more than 25%, with no treatment-related serious adverse events reported. The company is advancing the program in global registrational Phase 2/3 FALCON-HD trials, with more than 200 patients enrolled across the Phase 1/2 and Phase 2/3 programs.

Analysis

There is no direct public-equity expression because Skyhawk is private, but the data raise the competitive bar for Huntington programs with less convenient administration or single-mechanism biology. The most exposed public comparator is PTC Therapeutics (PTCT), whose oral HTT-lowering candidate votoplam could face a materially narrower differentiation case if SKY-0515’s dual-target profile and functional signal replicate in a controlled pivotal setting. uniQure (QURE) and Wave Life Sciences (WVE) retain differentiated gene-therapy and allele-selective approaches, respectively, but a credible once-daily oral disease-modifier would pressure their eventual commercial pricing and adoption assumptions, particularly in earlier-stage patients.

The near-term read-through should be limited: a small late-extension cohort benchmarked against weighted natural-history controls cannot establish causality, durability, or a clean dose-response. Attrition, post-baseline exclusions, and the absence of a concurrent long-duration placebo arm create meaningful optimism bias; the apparent acceleration of separation late in follow-up is precisely the pattern that requires replication. For the next 12-24 months, the decisive variables are placebo-controlled functional outcomes, discontinuation rates, neuropsychiatric safety, and whether protein lowering translates across disease stages rather than simply enriching for slower progressors.

Consensus may overvalue biomarker depth relative to commercial proof. Huntington has repeatedly produced mechanistically persuasive programs that failed on clinical benefit or tolerability, so this is more a validation of oral RNA-splicing as a modality than an investable efficacy conclusion today. If replicated, however, the second-order consequence is broader: orally delivered CNS RNA modulators could attract strategic partnering capital and raise platform values across private and public RNA-focused neurology developers, while making invasive CNS delivery platforms less attractive for chronic indications.

Key Decisions for Investors

• No directional trade on the announcement itself: Skyhawk is private and the key efficacy evidence lacks a contemporaneous long-duration control. Maintain an event watch rather than extrapolating this result into public neurodegeneration valuations.
• Place PTCT on a 1-3 month relative-underperformance watch versus XBI: initiate a tactical short only if management cannot articulate differentiated clinical efficacy, safety, or development timing for votoplam after the market digests competing oral-program data. Cover if PTCT reports a clearly superior placebo-controlled functional signal or meaningful partnering validation.
• Maintain QURE and WVE as volatility-driven catalyst names rather than using them as direct shorts. A confirmed oral competitor would be most negative to their long-term penetration and pricing assumptions, but positive gene-therapy or allele-selective data could still preserve clinically meaningful differentiation.
• For private-market and partnership monitoring, watch for Skyhawk financing, licensing, or pharma collaboration announcements over the next 6-12 months. A high-value transaction would validate platform optionality, but is not evidence that the pivotal program has been de-risked.